Buchumschlag

Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon: drug evaluation

Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed eff...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Furlanetto, Jenny (VerfasserIn) , Marmé, Frederik (VerfasserIn) , Loibl, Sibylle (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 7 Sep 2022
In: Future oncology
Year: 2022, Jahrgang: 18, Heft: 28, Pages: 3199-3215
ISSN:1744-8301
DOI:10.2217/fon-2022-0407
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/fon-2022-0407
Verlag, lizenzpflichtig, Volltext: http://www.futuremedicine.com/doi/10.2217/fon-2022-0407
Volltext
Verfasserangaben:Jenny Furlanetto, Frederik Marmé and Sibylle Loibl

MARC

LEADER 00000caa a22000002c 4500
001 1859927734
003 DE-627
005 20240329080735.0
007 cr uuu---uuuuu
008 230919s2022 xx |||||o 00| ||eng c
024 7 |a 10.2217/fon-2022-0407  |2 doi 
035 |a (DE-627)1859927734 
035 |a (DE-599)KXP1859927734 
035 |a (OCoLC)1425216806 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Furlanetto, Jenny  |e VerfasserIn  |0 (DE-588)1141798654  |0 (DE-627)1000750841  |0 (DE-576)494512636  |4 aut 
245 1 0 |a Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon  |b drug evaluation  |c Jenny Furlanetto, Frederik Marmé and Sibylle Loibl 
264 1 |c 7 Sep 2022 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 19.09.2023 
520 |a Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed efficacy and safety in several epithelial tumors. The phase III ASCENT trial led to the approval of SG (10 mg/kg, d1,8 q3w) in patients with advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior systemic therapies, including ≥1 for metastatic disease. The phase III TROPiCS-02 trial in heavily pretreated advanced hormone receptor (HR)-positive breast cancer has recently shown an improvement in progression-free survival for patients treated with SG compared to single-agent chemotherapy. The phase III post-neoadjuvant SASCIA study in early high-risk TNBC and HR-positive breast cancer is currently recruiting patients. 
650 4 |a antibody-drug conjugate 
650 4 |a early breast cancer 
650 4 |a metastatic breast cancer 
650 4 |a sacituzumab govitecan 
700 1 |a Marmé, Frederik  |d 1974-  |e VerfasserIn  |0 (DE-588)132561972  |0 (DE-627)52394893X  |0 (DE-576)299226549  |4 aut 
700 1 |a Loibl, Sibylle  |e VerfasserIn  |0 (DE-588)12433024X  |0 (DE-627)085790508  |0 (DE-576)294122753  |4 aut 
773 0 8 |i Enthalten in  |t Future oncology  |d London : Taylor & Francis, 2005  |g 18(2022), 28, Seite 3199-3215  |h Online-Ressource  |w (DE-627)484405055  |w (DE-600)2184533-5  |w (DE-576)398100217  |x 1744-8301  |7 nnas  |a Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon drug evaluation 
773 1 8 |g volume:18  |g year:2022  |g number:28  |g pages:3199-3215  |g extent:17  |a Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon drug evaluation 
856 4 0 |u https://doi.org/10.2217/fon-2022-0407  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://www.futuremedicine.com/doi/10.2217/fon-2022-0407  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230919 
993 |a Article 
994 |a 2022 
998 |g 132561972  |a Marmé, Frederik  |m 132561972:Marmé, Frederik  |d 60000  |d 61300  |d 50000  |e 60000PM132561972  |e 61300PM132561972  |e 50000PM132561972  |k 0/60000/  |k 1/60000/61300/  |k 0/50000/  |p 2 
999 |a KXP-PPN1859927734  |e 4377849654 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"language":["eng"],"part":{"issue":"28","text":"18(2022), 28, Seite 3199-3215","year":"2022","pages":"3199-3215","extent":"17","volume":"18"},"origin":[{"dateIssuedKey":"2005","publisher":"Taylor & Francis ; Future Medicine Ltd","dateIssuedDisp":"2005-","publisherPlace":"London ; London"}],"note":["Gesehen am 28.05.2024"],"pubHistory":["1.2005 -"],"title":[{"title_sort":"Future oncology","title":"Future oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon drug evaluationFuture oncology","recId":"484405055","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1744-8301"],"zdb":["2184533-5"],"eki":["484405055"]}}],"recId":"1859927734","physDesc":[{"extent":"17 S."}],"name":{"displayForm":["Jenny Furlanetto, Frederik Marmé and Sibylle Loibl"]},"id":{"eki":["1859927734"],"doi":["10.2217/fon-2022-0407"]},"title":[{"title_sort":"Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon","subtitle":"drug evaluation","title":"Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon"}],"note":["Gesehen am 19.09.2023"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"7 Sep 2022"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"person":[{"role":"aut","given":"Jenny","display":"Furlanetto, Jenny","family":"Furlanetto"},{"family":"Marmé","display":"Marmé, Frederik","given":"Frederik","role":"aut"},{"given":"Sibylle","role":"aut","display":"Loibl, Sibylle","family":"Loibl"}]} 
SRT |a FURLANETTOSACITUZUMA7202 

Ähnliche Einträge